Answers are grounded in this paper and cite their sources.
Shows differentiation of T follicular helper cells into TR1 cells, indicating a novel immune regulatory pathway.
T-regulatory-type-1 (TR1) cells are a subset of interleukin-10-producing but Foxp3 – Treg cells that arise in response to chronic antigenic stimulation. We have shown that systemic delivery of autoimmune disease-relevant peptide-major histocompatibility complex class II (pMHCII)-coated nanoparticles (pMHCII-NP) triggers the formation of large pools of disease-suppressing Foxp3 – TR1 cells from cognate T-follicular helper (TFH) cell precursors. Here we show that, upon treatment withdrawal, these Foxp3 – TR1 cells spontaneously differentiate into a novel immunoregulatory Foxp3 + TR1 subset that inherits epigenetic and transcriptional hallmarks of their precursors, including clonotypic T-cell receptors, and is distinct from other Foxp3 + Treg subsets. Whereas the transcription factor BLIMP-1 is dispensable for development of conventional Foxp3 + Treg cells, it is necessary for development of Foxp3 + TR1 cells. In a model of central nervous system autoimmunity, abrogation of BLIMP-1 or IL-10 expression in the Foxp3 – and/or Foxp3 + TR1 subsets inhibits their development or anti-encephalitogenic activity. Thus, the TFH-TR1 transdifferentiation pathway results in the generation of two distinct autoimmune disease-suppressing, IL-10-producing TR1 subsets that are distinguished by the expression of Foxp3 and Foxp3 target genes.
No takes yet. Share an insight, caveat, or question.
Garnica et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: